AU765983B2 - Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis - Google Patents

Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis Download PDF

Info

Publication number
AU765983B2
AU765983B2 AU51253/00A AU5125300A AU765983B2 AU 765983 B2 AU765983 B2 AU 765983B2 AU 51253/00 A AU51253/00 A AU 51253/00A AU 5125300 A AU5125300 A AU 5125300A AU 765983 B2 AU765983 B2 AU 765983B2
Authority
AU
Australia
Prior art keywords
bad
fragment
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51253/00A
Other languages
English (en)
Other versions
AU5125300A (en
Inventor
Xiao-Mai Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apoptosis Technology Inc
Original Assignee
Apoptosis Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoptosis Technology Inc filed Critical Apoptosis Technology Inc
Publication of AU5125300A publication Critical patent/AU5125300A/en
Application granted granted Critical
Publication of AU765983B2 publication Critical patent/AU765983B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU51253/00A 1999-05-28 2000-05-30 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis Ceased AU765983B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13678399P 1999-05-28 1999-05-28
US60/136783 1999-05-28
PCT/US2000/011864 WO2001010888A1 (fr) 1999-05-28 2000-05-30 Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose

Publications (2)

Publication Number Publication Date
AU5125300A AU5125300A (en) 2001-03-05
AU765983B2 true AU765983B2 (en) 2003-10-09

Family

ID=22474341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51253/00A Ceased AU765983B2 (en) 1999-05-28 2000-05-30 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis

Country Status (5)

Country Link
EP (1) EP1181306A4 (fr)
JP (1) JP2003506071A (fr)
AU (1) AU765983B2 (fr)
CA (1) CA2373814A1 (fr)
WO (1) WO2001010888A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1273654A1 (fr) * 2001-07-05 2003-01-08 Schering Aktiengesellschaft BAD comme substrat pour PPC2
US6933127B2 (en) 2001-07-05 2005-08-23 Eucro European Contract Research Gmbh & Co. Kg Substrate for PP2C
WO2003018058A1 (fr) * 2001-08-22 2003-03-06 Mitsuhiro Yokota Inhibiteur d'apoptose de cellules myocardiques
WO2003042239A1 (fr) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibant la signalisation des gtpases de type ras
ES2262765T3 (es) * 2002-03-07 2006-12-01 Institut Pasteur Metodos para tamizar compuestos que modulan apoptosis, compuestos identificados por dichos metodos y uso de dichos compuestos como agentes terapeuticos.
CA2480661A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Methode de modulation d'activite cellulaire
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1661912A1 (fr) * 2004-11-29 2006-05-31 Xigen S.A. Protéine de fusion comprenant un domaine BH3 d'une protéine BH3-only
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2007035494A2 (fr) * 2005-09-16 2007-03-29 The Regents Of The University Of California Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite
CN101680886A (zh) * 2007-03-20 2010-03-24 沃尔特及伊莱萨霍尔医学研究院 筛选方法
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012328A2 (fr) * 1996-09-20 1998-03-26 Idun Pharmaceuticals, Incorporated Polypeptides de bad humaine codant des acides nucleiques et leurs procedes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012328A2 (fr) * 1996-09-20 1998-03-26 Idun Pharmaceuticals, Incorporated Polypeptides de bad humaine codant des acides nucleiques et leurs procedes d'utilisation

Also Published As

Publication number Publication date
WO2001010888A1 (fr) 2001-02-15
JP2003506071A (ja) 2003-02-18
AU5125300A (en) 2001-03-05
CA2373814A1 (fr) 2001-02-15
EP1181306A1 (fr) 2002-02-27
EP1181306A4 (fr) 2003-06-18

Similar Documents

Publication Publication Date Title
AU765983B2 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
US5856445A (en) Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
AU722622B2 (en) BH3 interacting domain death agonist
Foster et al. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation
WO1998009980A9 (fr) Agoniste de mort a domaine d'interaction bh3
US7709600B2 (en) Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
US7982002B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US7196182B2 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
US20090215666A1 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
AU784008B2 (en) Card proteins involved in cell death regulation
US7193044B1 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
WO1998009643A1 (fr) Modulation de l'apoptoste par phophorylation de la serine du regulateur de mort cellulaire associe a bcl-xl/bcl-2
US7041783B2 (en) Survivin-binding proteins, encoding nucleic acids, and methods of use
AU779258B2 (en) Human suppressor of fused
US7144996B1 (en) Nucleic acid encoding human suppressor of fused

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)